Literature DB >> 12024076

Supplemental oxygen reduces the incidence of postoperative nausea and vomiting.

O Akça1, D I Sessler.   

Abstract

Postoperative nausea and vomiting (PONV) are unpleasent for patients and increase the risk of aspiration pneumonia. PONV is the leading cause of unexpected admission following planned day surgery. Despite new anaesthetic drugs and antiemetics, the incidence of PONV remains high. The incidence of PONV depends numerous factors including age, gender, obesity, anxiety, gastroparesis, history of motion sickness, previous PONV, and the duration and type of surgery. Anaesthesia related factors include premedication, ventilation techniques, and postoperative pain management. Recently, the intraoperative inspired oxygen concentration was identified as a factor that influences PONV. Among the three studies that evaluated intraoperative supplemental O2 for prevention of PONV, two found that it halves PONV while the third failed to identify any benefit. Since supplemental O2 is inexpensive and essentially risk-free, it appears preferable to pharmacologic anti-emetics for prevention of PONV in abdominal surgery.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12024076

Source DB:  PubMed          Journal:  Minerva Anestesiol        ISSN: 0375-9393            Impact factor:   3.051


  3 in total

1.  The effect of supplemental 70% oxygen on postoperative nausea and vomiting in patients undergoing inguinal hernia surgery.

Authors:  S H Sadrolsadat; M Shoroghi; F Farahbakhsh; R Shariat Moharreri; M Sheikhvatan; A Abbasi
Journal:  Hernia       Date:  2007-11-17       Impact factor: 4.739

Review 2.  Recent advances in mechanical ventilation in patients without acute respiratory distress syndrome.

Authors:  Ary Serpa Neto; Roberto R Filho; Leonardo L Rocha; Marcus J Schultz
Journal:  F1000Prime Rep       Date:  2014-12-01

3.  The acupoint herbal plaster for the prevention and treatment of postoperative nausea and vomiting after PLIF with general anesthesia: study protocol for a multicenter randomized controlled trial.

Authors:  Huiqing Xu; Xu Wei; Ranxing Zhang; Ling Li; Zhijun Zhang; Ruo Jia; Xiaofei Zhang; Xiumei Gao; Xicheng Dong; Junjun Pan
Journal:  Trials       Date:  2021-01-22       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.